Used in the treatment of B-cell-related disorders such as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and autoimmune diseases like rheumatoid arthritis and multiple sclerosis. It selectively targets CD20 proteins on the surface of B-cells, leading to their depletion through mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Due to its high specificity, it helps reduce disease activity while sparing stem cells and plasma cells, allowing for preserved immunoglobulin levels. It serves as a reference in biosimilar development and preclinical research to benchmark efficacy and mechanism of action of new anti-CD20 antibodies.